Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - Poster

Iain Squire¹, Faiez Zannad², Javed Butler³, Gerasimos Filippatos⁴, Stuart J. Pocock⁵, Waheed Jamal⁶, Janet Schnee⁷, Karen Kimura⁸, Cordula Zeller⁹, Martina Brueckmann⁶,10 Stefan D. Anker¹¹, Milton Packer¹², for the EMPEROR-Reduced Trial Committees and Investigators

1 University of Leicester, Department of Cardiovascular Sciences, and NIHR Biomedical Research Centre, Leicester, UK
2 Inserm INI-CRCT, CHRU, Université de Lorraine, Nancy, France
3 University of Mississippi School of Medicine, Jackson, MI, USA
4 Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece, and School of Medicine, Athens University Hospital Attikon, Athens, Greece
5 Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
6 Boehringer Ingelheim International GmbH, Ingelheim, Germany
7 Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA
8 Boehringer Ingelheim Canada Ltd., Burlington, ON, Canada
9 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
10 Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany
11 Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site, Berlin, Germany, and Charité Universitätsmedizin, Berlin, Germany
12 Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA, and Imperial College, London, UK